期刊文献+

介导siRNA传递的非病毒载体及其研究进展 被引量:11

Research advances in non-viral-based siRNA delivery systems
原文传递
导出
摘要 RNA干扰(RNAi)是一种疾病治疗的新途径,其中小干扰RNA(siRNA)可破坏mRNA的完整性,抑制疾病相关基因的表达,而开发安全有效的siRNA传递载体仍面临巨大挑战。相较于病毒载体系统,非病毒载体系统安全性高、负载量大、生物相容性好,更适用于疾病治疗。综述了可用于siRNA传递的一些非病毒载体(包括脂质体、细胞穿膜肽、水凝胶、树枝状大分子、磷酸钙、碳纳米管等),阐述了载体与siRNA的结合,靶向疾病组织或细胞并诱导特异基因沉默的机制、瓶颈问题等。 RNA interference (RNAi) is a new mechanism triggered by small interfering RNA (siRNA), which represents a promising gene therapy strategy by destroying the integrity of the complementary mRNA in the cytoplasm, causing sequence-specific posttranscriptional gene silencing. Systemic siRNA therapy is hampered by inefficient delivery of its carrier. Compared with viral-based delivery systems, non-viral-based delivery systems are safer, and have higher load, greater cellular compatibility, so they are more suitable for clinical application. In general, the non-viral carriers include cation lipid-based carriers, cation cell-penetrating peptides, dendrimers, cation polymers, inorganic nanomaterials. This review describes the recent types and advantage in siRNA delivery using non-viral-based siRNA delivery systems.
出处 《生命科学》 CSCD 2014年第4期392-399,共8页 Chinese Bulletin of Life Sciences
基金 浙江理工大学521人才培养计划 浙江省自然科学基金项目(Y207217) 国家自然科学基金项目(51272236 51002139 51172207)
关键词 SIRNA 非病毒载体 基因治疗 siRNA non-viral carriers gene therapy
  • 相关文献

参考文献7

二级参考文献143

共引文献54

同被引文献119

  • 1张永云,黄英,杨明华,潘洪彬,李卫真,赵素梅,高士争.ADD1基因多态性与乌金猪肌内脂肪含量的关系[J].云南农业大学学报,2013,25(2):196-200. 被引量:10
  • 2张中华,侯永泰.siRNA制备技术的研究进展[J].生命科学,2004,16(4):231-235. 被引量:12
  • 3WEIBERG A, BELLINGER M, JIN H. Conversations between kingdoms: small RNAs[J]. Curr Opin Biotechnol, 2015, 32: 207-215.
  • 4KOENIG O, WALKER T, PERLE N, et al. New aspects of gene- silencing for the treatment of cardiovascular diseases [J]. Pharmaceuticals (Basel), 2013, 6(7): 881-914.
  • 5YAMANAKA S, MEHTA S, REYES-TURCU FE, et al. RNAi triggered by specialized machinery silences developmental genes and retrotransposons[J]. Nature, 2013, 493 (7433): 557-560.
  • 6MAILLARD PV, CIAUDO C, MARCHAIS A, et ol. Antiviral RNA interference in mammalian cells[J]. Science, 2013, 342 (6155) : 235-238.
  • 7FITZGERALD K, FRANK- KAMENETSKY M, SHULGA- MORSKAYA S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single- blind, placebo- controlled, phase 1 trial[J]. Lancet, 2014, 383(9911): 60-68.
  • 8CARTHEW RW, SONTHEIMER EJ. Origins and mechanisms of miRNAs and siRNAs[J]. Cell, 2009, 136(4) : 642-655.
  • 9SIOUD M. RNA interference: mechanisms, technical challenges, and therapeutic opportunities[J]. Methods Mol Biol, 2015, 1218: 1-15.
  • 10LI D, LI J, AN Y, et al. Doxorubicin- induced apoptosis in H9c2 cardiomyocytes by NF-KB dependent PUMA upregulation [J]. Eur Rev Med Pharmacol Sci, 2013, 17(17): 2323-2329.

引证文献11

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部